Proteoglycans in liver cancer

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 379-393

  Baghy, Kornélia ^a   Tátrai, Péter ^a   Regös, Eszter ^a   Kovalszky, Ilona ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cancer; Cell regulation; Heparan sulfate; Liver; Proteoglycans

Indexed keywords

AGGRECAN; AGRIN; ASPORIN; BIGLYCAN; BREVICAN; COLLAGEN TYPE 18; DECORIN; ENDOCAN; ENDOSTATIN; FIBROMODULIN; GLYPICAN; HEPARAN SULFATE; KERATOCAN; LEUCINE; LUMICAN; NEUROCAN; PERLECAN; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; SERGLYCIN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; UNCLASSIFIED DRUG; VERSICAN; GLYCOSAMINOGLYCAN; PROTEOHEPARAN SULFATE; SDC1 PROTEIN, HUMAN; VCAN PROTEIN, HUMAN;

CANCER GROWTH; EXPERIMENTAL LIVER NEOPLASM; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER FUNCTION; LIVER PROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM;

AGRIN; ANIMALS; CARCINOMA, HEPATOCELLULAR; GLYCOSAMINOGLYCANS; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; PROTEOGLYCANS; SYNDECAN-1; VERSICANS;

EID: 84953384953     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.379     Document Type: Review

References (179)

1. Fransson LA, Havsmark B, Chiarugi VP. Co-polymeric glycosaminoglycans in transformed cells. Transformationdependent changes in the co-polymeric structure of heparan sulphate. Biochem J 1982; 201: 233-240 [PMID: 6282259]
2. Kjellén L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60: 443-475 [PMID: 1883201 DOI: 10.1146/annurev.bi.60.070191.002303]
3. Roskams T, Moshage H, De Vos R, Guido D, Yap P, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995; 21: 950-958 [PMID: 7705805]
4. Kovalszky I, Pogany G, Molnar G, Jeney A, Lapis K, Karacsonyi S, Szecseny A, Iozzo RV. Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem Biophys Res Commun 1990; 167: 883-890 [PMID: 2157432]
5. Lv H, Yu G, Sun L, Zhang Z, Zhao X, Chai W. Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 2007; 72: 347-356 [PMID: 18187957 DOI: 10.1159/000113145]
6. Nakamura N, Kojima J. Changes in charge density of heparan sulfate isolated from cancerous human liver tissue. Cancer Res 1981; 41: 278-283 [PMID: 6449994]
7. Tátrai P, Egedi K, Somorácz A, van Kuppevelt TH, Ten Dam G, Lyon M, Deakin JA, Kiss A, Schaff Z, Kovalszky I. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem 2010; 58: 429-441 [PMID: 20124094 DOI: 10.1369/jhc.2010.955161]
8. Dudás J, Ramadori G, Knittel T, Neubauer K, Raddatz D, Egedy K, Kovalszky I. Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cisacting elements: altered potential of hepatocellular carcinoma heparan sulphate. Biochem J 2000; 350 Pt 1: 245-251 [PMID: 10926850]
9. Kovalszky I, Dudás J, Oláh-Nagy J, Pogány G, Töváry J, Timár J, Kopper L, Jeney A, Iozzo RV. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 1998; 183: 11-23 [PMID: 9655174]
10. Kreuger J, Spillmann D, Li JP, Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 2006; 174: 323-327 [PMID: 16880267 DOI: 10.1083/jcb.200604035]
11. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994; 269: 11216-11223 [PMID: 8157651]
12. Tumova S, Woods A , Couchman J R Heparansul fate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000; 32: 269-288 [PMID: 10716625]
13. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellén L, Claesson-Welsh L. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 2006; 10: 625-634 [PMID: 16678777 DOI: 10.1016/j.devcel.2006.03.009]
14. Friand V, Haddad O, Papy-Garcia D, Hlawaty H, Vassy R, Hamma-Kourbali Y, Perret GY, Courty J, Baleux F, Oudar O, Gattegno L, Sutton A, Charnaux N. Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology 2009; 19: 1511-1524 [PMID: 19717493 DOI: 10.1093/glycob/cwp130]
15. Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, Perret GY, Courty J, Gattegno L, Charnaux N. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther 2007; 6: 2948-2958 [PMID: 18025279 DOI: 10.1158/1535-7163.MCT-07-0114]
16. Kobayashi F, Yamada S, Taguwa S, Kataoka C, Naito S, Hama Y, Tani H, Matsuura Y, Sugahara K. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj J 2012; 29: 211-220 [PMID: 22660965 DOI: 10.1007/s10719-012-9388-z]
17. Dudás J, Bocsi J, Fullár A, Baghy K, Füle T, Kudaibergenova S, Kovalszky I. Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action. Biomed Res Int 2014; 2014: 765794 [PMID: 25309924 DOI: 10.1155/2014/765794]
18. Richardson TP, Trinkaus-Randall V, Nugent MA. Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci 2001; 114: 1613-1623 [PMID: 11309193]
19. Stewart MD, Sanderson RD. Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biol 2014; 35: 56-59 [PMID: 24309018 DOI: 10.1016/j.matbio.2013.10.009]
20. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004; 2: 3 [PMID: 14711376 DOI: 10.1186/1477-7827-2-3]
21. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009; 119: 3236-3245 [PMID: 19805913 DOI: 10.1172/JCI38251]
22. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Büchler MW. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000; 88: 12-20 [PMID: 10962434]
23. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997; 74: 482-491 [PMID: 9355969]
24. Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm 2012; 80: 179-188 [PMID: 22396913 DOI: 10.3797/scipharm.1110-07]
25. Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev 2013; 22: 1343-1352 [PMID: 23780836 DOI: 10.1158/1055-9965.EPI-13-0179]
26. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, Sanderson RD. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 2013; 280: 2294-2306 [PMID: 23374281 DOI: 10.1111/febs.12168]
27. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224 [PMID: 18505598 DOI: 10.1186/gb-2008-9-5-224]
28. Yan D, Lin X. Shaping morphogen gradients by proteoglycans. Cold Spring Harb Perspect Biol 2009; 1: a002493 [PMID: 20066107 DOI: 10.1101/cshperspect.a002493]
29. Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol 2014; 35: 248-252 [PMID: 24412155 DOI: 10.1016/j.matbio.2013.12.007]
30. Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 2012; 60: 9-21 [PMID: 22205677 DOI: 10.1369/0022155411428469]
31. Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, Afratis N, Lim HC, Couchman JR, Filmus J, Sanderson RD, Schaefer L, Iozzo RV, Karamanos NK. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta 2015; 1855: 276-300 [PMID: 25829250 DOI: 10.1016/j.bbcan.2015.03.006]
32. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-247 [PMID: 8589713 DOI: 10.1038/ng0396-241]
33. Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001; 23: 496-499 [PMID: 11878776]
34. Ota S, Hishinuma M, Yamauchi N, Goto A, Morikawa T, Fujimura T, Kitamura T, Kodama T, Aburatani H, Fukayama M. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch 2006; 449: 308-314 [PMID: 16896894 DOI: 10.1007/s00428-006-0238-x]
35. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612-6621 [PMID: 15475451 DOI: 10.1158/1078-0432. CCR-04-0348]
36. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Büchler MW. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001; 48: 558-564 [PMID: 11247902]
37. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97 [PMID: 12851874]
38. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999; 59: 807-810 [PMID: 10029067]
39. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000; 19: 410-416 [PMID: 10656689 DOI: 10.1038/sj.onc.1203322]
40. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001; 20: 7408-7412 [PMID: 11704870 DOI: 10.1038/sj.onc.1204925]
41. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Caldwell CW, Huang TH. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 2001; 61: 8375-8380 [PMID: 11731411]
42. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008; 7: 2787-2790 [PMID: 18787398]
43. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254 [PMID: 16024626 DOI: 10.1158/0008-5472.CAN-04-4244]
44. Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol 2015; 46: 1275-1285 [PMID: 25572615 DOI: 10.3892/ijo.2015.2827]
45. Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011; 47: 333-338 [PMID: 21112773 DOI: 10.1016/j.ejca.2010.10.024]
46. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006; 37: 1435-1441 [PMID: 16949914 DOI: 10.1016/j.humpath.2006.05.016]
47. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-1411 [PMID: 17063081 DOI: 10.1097/01.pas.0000213323.97294.9a]
48. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664 [PMID: 19177576 DOI: 10.1002/hep.22709]
49. Jain D. Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S67-S73 [PMID: 25755614 DOI: 10.1016/j.jceh.2014.03.047]
50. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-734 [PMID: 17326147 DOI: 10.1002/hep.21531]
51. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 2012; 138: 203-210 [PMID: 22904131 DOI: 10.1309/AJCPK1ZC9WNHCCMU]
52. Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H, Xian ZH, Dong W, Liu YK, Cong WM, Wu MC. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer 2013; 13: 161 [PMID: 23537217 DOI: 10.1186/1471-2407-13-161]
53. Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem 2013; 61: 639-648 [PMID: 23686365 DOI: 10.1369/0022155413492771]
54. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, Jin SY, Morenghi E, Park YN, Roncalli M. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754 [PMID: 19231003 DOI: 10.1016/j.jhep.2008.11.014]
55. Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI-Anchored proteins from the cell surface. Biochem J 2008; 410: 503-511 [PMID: 17967162 DOI: 10.1042/BJ20070511]
56. Liu XF, Hu ZD, Liu XC, Cao Y, Ding CM, Hu CJ. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-Analysis. Clin Biochem 2014; 47: 196-200 [PMID: 24362268 DOI: 10.1016/j.clinbiochem.2013.12.0 07]
57. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 2014; 588: 377-382 [PMID: 24140348 DOI: 10.1016/j.febslet.2013.10.002]
58. Bezakova G, Ruegg MA. New insights into the roles of agrin. Nat Rev Mol Cell Biol 2003; 4: 295-308 [PMID: 12671652 DOI: 10.1038/nrm1074]
59. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135: 334-342 [PMID: 18848351 DOI: 10.1016/j.cell.2008.10.002]
60. Bányai L, Sonderegger P, Patthy L. Agrin binds BMP2, BMP4 and TGFbeta1. PLoS One 2010; 5: e10758 [PMID: 20505824 DOI: 10.1371/journal.pone.0010758]
61. Reist NE, Werle MJ, McMahan UJ. Agrin released by motor neurons induces the aggregation of acetylcholine receptors at neuromuscular junctions. Neuron 1992; 8: 865-868 [PMID: 1316763]
62. Daniels MP. The role of agrin in synaptic development, plasticity and signaling in the central nervous system. Neurochem Int 2012; 61: 848-853 [PMID: 22414531 DOI: 10.1016/j.neuint.2012.02.028]
63. Khan AA, Bose C, Yam LS, Soloski MJ, Rupp F. Physiological regulation of the immunological synapse by agrin. Science 2001; 292: 1681-1686 [PMID: 11349136 DOI: 10.1126/science.1056594]
64. Mazzon C, Anselmo A, Cibella J, Soldani C, Destro A, Kim N, Roncalli M, Burden SJ, Dustin ML, Sarukhan A, Viola A. The critical role of agrin in the hematopoietic stem cell niche. Blood 2011; 118: 2733-2742 [PMID: 21653324 DOI: 10.1182/blood-2011-01-331272]
65. Song J, Lokmic Z, Lämmermann T, Rolf J, Wu C, Zhang X, Hallmann R, Hannocks MJ, Horn N, Ruegg MA, Sonnenberg A, Georges-Labouesse E, Winkler TH, Kearney JF, Cardell S, Sorokin L. Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proc Natl Acad Sci USA 2013; 110: E2915-E2924 [PMID: 23847204 DOI: 10.1073/pnas.1218131110]
66. Mazzon C, Anselmo A, Soldani C, Cibella J, Ploia C, Moalli F, Burden SJ, Dustin ML, Sarukhan A, Viola A. Agrin is required for survival and function of monocytic cells. Blood 2012; 119: 5502-5511 [PMID: 22517892 DOI: 10.1182/blood-2011-09-382812]
67. Barber AJ, Lieth E. Agrin accumulates in the brain microvascular basal lamina during development of the blood-brain barrier. Dev Dyn 1997; 208: 62-74 [PMID: 8989521]
68. Groffen AJ, Buskens CA, van Kuppevelt TH, Veerkamp JH, Monnens LA, van den Heuvel LP. Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. Eur J Biochem 1998; 254: 123-128 [PMID: 9652404]
69. Groffen AJ, Ruegg MA, Dijkman H, van de Velden TJ, Buskens CA, van den Born J, Assmann KJ, Monnens LA, Veerkamp JH, van den Heuvel LP. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998; 46: 19-27 [PMID: 9405491]
70. Liebner S, Czupalla CJ, Wolburg H. Current concepts of bloodbrain barrier development. Int J Dev Biol 2011; 55: 467-476 [PMID: 21769778 DOI: 10.1387/ijdb.103224sl]
71. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010; 9: 2048-2062 [PMID: 20551380 DOI: 10.1074/mcp.M110.001693]
72. Gesemann M, Brancaccio A, Schumacher B, Ruegg MA. Agrin is a high-Affinity binding protein of dystroglycan in non-muscle tissue. J Biol Chem 1998; 273: 600-605 [PMID: 9417121]
73. Tátrai P, Dudás J, Batmunkh E, Máthé M, Zalatnai A, Schaff Z, Ramadori G, Kovalszky I. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest 2006; 86: 1149-1160 [PMID: 16983329 DOI: 10.1038/labinvest.3700475]
74. Vestentoft PS. Development and molecular composition of the hepatic progenitor cell niche. Dan Med J 2013; 60: B4640 [PMID: 23673270]
75. Tátrai P, Somorácz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol 2009; 33: 874-885 [PMID: 19194276 DOI: 10.1097/PAS.0b013e318194b3ea]
76. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol 2010; 41: 1310-1319 [PMID: 20471664 DOI: 10.1016/j.humpath.2009.10.029]
77. Chakraborty S, Lakshmanan M, Swa HL, Chen J, Zhang X, Ong YS, Loo LS, Aknclar SC, Gunaratne J, Tergaonkar V, Hui KM, Hong W. An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat Commun 2015; 6: 6184 [PMID: 25630468 DOI: 10.1038/ncomms7184]
78. Kawahara R, Granato DC, Carnielli CM, Cervigne NK, Oliveria CE, Rivera C, Yokoo S, Fonseca FP, Lopes M, Santos-Silva AR, Graner E, Coletta RD, Paes Leme AF. Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. PLoS One 2014; 9: e115004 [PMID: 25506919 DOI: 10.1371/journal. pone.0115004]
79. Reine TM, Kusche-Gullberg M, Feta A, Jenssen T, Kolset SO. Heparan sulfate expression is affected by inflammatory stimuli in primary human endothelial cells. Glycoconj J 2012; 29: 67-76 [PMID: 22187328 DOI: 10.1007/s10719-011-9365-y]
80. Steiner E, Enzmann GU, Lyck R, Lin S, Rüegg MA, Kröger S, Engelhardt B. The heparan sulfate proteoglycan agrin contributes to barrier properties of mouse brain endothelial cells by stabilizing adherens junctions. Cell Tissue Res 2014; 358: 465-479 [PMID: 25107608 DOI: 10.1007/s00441-014-1969-7]
81. Gallai M, Kovalszky I, Knittel T, Neubauer K, Armbrust T, Ramadori G. Expression of extracellular matrix proteoglycans perlecan and decorin in carbon-tetrachloride-injured rat liver and in isolated liver cells. Am J Pathol 1996; 148: 1463-1471 [PMID: 8623917]
82. Iozzo RV. Perlecan: a gem of a proteoglycan. Matrix Biol 1994; 14: 203-208 [PMID: 7921536]
83. Vischer P, Feitsma K, Schön P, Völker W. Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells. Eur J Cell Biol 1997; 73: 332-343 [PMID: 9270876]
84. Whitelock JM, Melrose J, Iozzo RV. Diverse cell signaling events modulated by perlecan. Biochemistry 2008; 47: 11174-11183 [PMID: 18826258 DOI: 10.1021/bi8013938]
85. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011; 15: 1013-1031 [PMID: 21155971 DOI: 10.1111/j.1582-4934.2010.01236.x]
86. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003; 278: 4238-4249 [PMID: 12435733 DOI: 10.1074/jbc.M210445200]
87. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Höök M, Reed CC, Iozzo RV. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004; 166: 97-109 [PMID: 15240572 DOI: 10.1083/jcb.200401150]
88. Bix G, Iozzo RV. Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. Microsc Res Tech 2008; 71: 339-348 [PMID: 18300285 DOI: 10.1002/jemt.20562]
89. Iozzo RV, Zoeller JJ, Nyström A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol Cells 2009; 27: 503-513 [PMID: 19466598 DOI: 10.1007/s10059-009-0069-0]
90. Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol 2011; 30: 83-92 [PMID: 21163348 DOI: 10.1016/j.matbio.2010.11.001]
91. Tátrai P, Kovalszky I. Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update. In: Lau JWY, editor. Hepatocellular Carcinoma-Basic Research: InTech, 2012: 171-200
92. Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion JP, Pihlajaniemi T, Clement B. Tumor hepatocytes and basement membrane-Producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology 2001; 33: 868-876 [PMID: 11283851 DOI: 10.1053/jhep.2001.23189]
93. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004; 130: 307-319 [PMID: 15034787 DOI: 10.1007/s00432-003-0530-y]
94. Musso O, Rehn M, Théret N, Turlin B, Bioulac-Sage P, Lotrian D, Campion JP, Pihlajaniemi T, Clément B. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res 2001; 61: 45-49 [PMID: 11196195]
95. Quélard D, Lavergne E, Hendaoui I, Elamaa H, Tiirola U, Heljasvaara R, Pihlajaniemi T, Clément B, Musso O. A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/betacatenin signaling. PLoS One 2008; 3: e1878 [PMID: 18382662 DOI: 10.1371/journal.pone.0001878]
96. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607 [PMID: 16376330 DOI: 10.1016/j.yexcr.2005.11.015]
97. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009; 28: 177-183 [PMID: 19259624 DOI: 10.1007/s10555-008-9175-2]
98. Szarvas T, László V, Vom Dorp F, Reis H, Szendröi A, Romics I, Tilki D, Rübben H, Ergün S. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients'prognosis in bladder cancer. Int J Cancer 2012; 130: 2922-2929 [PMID: 21815140 DOI: 10.1002/ijc.26343]
99. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37 [PMID: 16168566 DOI: 10.1016/j.bbcan.2005.08.004]
100. Delehedde M, Devenyns L, Maurage CA, Vivés RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013; 2013: 705027 [PMID: 23606845 DOI: 10.1155/2013/705027]
101. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009; 54: 389-394 [PMID: 18592377 DOI: 10.1007/s10620-008-0346-3]
102. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 2014; 5: 221-230 [PMID: 24665346 DOI: 10.7150/jca.7691]
103. Iozzo RV, Schaefer L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol 2015; 42: 11-55 [PMID: 25701227 DOI: 10.1016/j.matbio.2015.02.003]
104. Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A, Karamanos NK, Theocharis AD. Serglycin: at the crossroad of inflammation and malignancy. Front Oncol 2014; 3: 327 [PMID: 24455486 DOI: 10.3389/fonc.2013.00327]
105. He L, Zhou X, Qu C, Tang Y, Zhang Q, Hong J. Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. Med Oncol 2013; 30: 707 [PMID: 23996242 DOI: 10.1007/s12032-013-0707-4]
106. Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 1996; 10: 598-614 [PMID: 8621059]
107. Schaefer L, Iozzo RV. Biological functions of the small leucinerich proteoglycans: from genetics to signal transduction. J Biol Chem 2008; 283: 21305-21309 [PMID: 18463092]
108. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999; 274: 18843-18846 [PMID: 10383378]
109. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010; 29: 248-253 [PMID: 20080181 DOI: 10.1016/j.matbio.2010.01.001]
110. Iozzo RV. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997; 32: 141-174 [PMID: 9145286]
111. Schönherr E, Hausser H, Beavan L, Kresse H. Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J Biol Chem 1995; 270: 8877-8883 [PMID: 7721795]
112. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76 [PMID: 17295177 DOI: 10.1055/s-2006-960171]
113. Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 2009; 185: 743-754 [PMID: 19433454]
114. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, Gomella LG, Owens RC, Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2011; 286: 34712-34721 [PMID: 21840990 DOI: 10.1074/jbc. M111.262766]
115. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Gröne HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am J Pathol 2007; 170: 301-315 [PMID: 17200203]
116. Schönherr E, Sunderkötter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005; 280: 15767-15772 [PMID: 15701628]
117. Schaefer L, Iozzo RV. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 2012; 22: 56-57 [PMID: 22326829 DOI: 10.1016/j.gde.2011.12.002]
118. Seidler DG. The galactosaminoglycan-containing decorin and its impact on diseases. Curr Opin Struct Biol 2012; 22: 578-582 [PMID: 22877511 DOI: 10.1016/j.sbi.2012.07.012]
119. Baghy K, Horváth Z, Reg?s E, Kiss K, Schaff Z, Iozzo RV, Kovalszky I. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J 2013; 280: 2150-2164 [PMID: 23448253 DOI: 10.1111/febs.12215]
120. Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, Evans B, Schaefer L, Peiper SC, Wang ZX, Iozzo RV. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS One 2012; 7: e45559 [PMID: 23029096 DOI: 10.1371/journal.pone.0045559]
121. Morrione A, Neill T, Iozzo RV. Dichotomy of decorin activity on the insulin-like growth factor-I system. FEBS J 2013; 280: 2138-2149 [PMID: 23351020 DOI: 10.1111/febs.12149]
122. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, Iozzo RV. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 2005; 280: 32468-32479 [PMID: 15994311]
123. Dudás J, Kovalszky I, Gallai M, Nagy JO, Schaff Z, Knittel T, Mehde M, Neubauer K, Szalay F, Ramadori G. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am J Clin Pathol 2001; 115: 725-735 [PMID: 11345837]
124. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281-284 [PMID: 2374594]
125. Zhang Z, Li XJ, Liu Y, Zhang X, Li YY, Xu WS. Recombinant human decorin inhibits cell proliferation and downregulates TGFbeta1 production in hypertrophic scar fibroblasts. Burns 2007; 33: 634-641 [PMID: 17374457]
126. Cabello-Verrugio C, Brandan E. A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J Biol Chem 2007; 282: 18842-18850 [PMID: 17485468 DOI: 10.1074/jbc.M700243200]
127. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423 [PMID: 8597951]
128. Shi YF, Zhang Q, Cheung PY, Shi L, Fong CC, Zhang Y, Tzang CH, Chan BP, Fong WF, Chun J, Kung HF, Yang M. Effects of rhDecorin on TGF-beta1 induced human hepatic stellate cells LX-2 activation. Biochim Biophys Acta 2006; 1760: 1587-1595 [PMID: 17067743]
129. Baghy K, Dezso K, László V, Fullár A, Péterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, Kovalszky I. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 2011; 91: 439-451 [PMID: 20956977 DOI: 10.1038/labinvest.2010.172]
130. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005; 29: 121S-131S [PMID: 16344596]
131. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV. Decorin antagonizes Met receptor activity and downregulates {beta}-catenin and Myc levels. J Biol Chem 2010; 285: 42075-42085 [PMID: 20974860 DOI: 10.1074/jbc.M110.172841]
132. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 1997; 100: 149-157 [PMID: 9202067]
133. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002; 14: 382-387 [PMID: 12521301]
134. Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe M, Sato C. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br J Cancer 2001; 85: 228-234 [PMID: 11461082]
135. Shangguan JY, Dou KF, Li X, Hu XJ, Zhang FQ, Yong ZS, Ti ZY. [Effects and mechanism of decorin on the proliferation of HuH7 hepatoma carcinoma cells in vitro]. Xibao Yu Fenzi Mianyixue Zazhi 2009; 25: 780-782 [PMID: 19737460]
136. Hamid AS, Li J, Wang Y, Wu X, Ali HA, Du Z, Bo L, Zhang Y, Zhang G. Recombinant human decorin upregulates p57KIP2 expression in HepG2 hepatoma cell lines. Mol Med Rep 2013; 8: 511-516 [PMID: 23754492 DOI: 10.3892/mmr.2013.1510]
137. Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS, Zhang G. Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther 2012; 5: 143-152 [PMID: 22927763 DOI: 10.2147/OTT.S32918]
138. Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 2003; 17: 464-466 [PMID: 12631584]
139. Horváth Z, Kovalszky I, Fullár A, Kiss K, Schaff Z, Iozzo RV, Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol 2014; 35: 194-205 [PMID: 24361483 DOI: 10.1016/j.matbio.2013.11.004]
140. Meyer DH, Krull N, Dreher KL, Gressner AM. Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors. Hepatology 1992; 16: 204-216 [PMID: 1618472]
141. Gressner AM, Krull N, Bachem MG. Regulation of proteoglycan expression in fibrotic liver and cultured fat-storing cells. Pathol Res Pract 1994; 190: 864-882 [PMID: 7899135 DOI: 10.1016/S0344-0338(11)80990-8]
142. Högemann B, Edel G, Schwarz K, Krech R, Kresse H. Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract 1997; 193: 747-751 [PMID: 9521506 DOI: 10.1016/S0344-0338(97)80052-0]
143. Lorenzo P, Aspberg A, Onnerfjord P, Bayliss MT, Neame PJ, Heinegard D. Identification and characterization of asporin. a novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. J Biol Chem 2001; 276: 12201-12211 [PMID: 11152692 DOI: 10.1074/jbc.M010932200]
144. Henry SP, Takanosu M, Boyd TC, Mayne PM, Eberspaecher H, Zhou W, de Crombrugghe B, Hook M, Mayne R. Expression pattern and gene characterization of asporin. a newly discovered member of the leucine-rich repeat protein family. J Biol Chem 2001; 276: 12212-12221 [PMID: 11152695 DOI: 10.1074/jbc.M011290200]
145. Satoyoshi R, Kuriyama S, Aiba N, Yashiro M, Tanaka M. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-Associated fibroblasts. Oncogene 2015; 34: 650-660 [PMID: 24441039 DOI: 10.1038/onc.2013.584]
146. Nakajima M, Kizawa H, Saitoh M, Kou I, Miyazono K, Ikegawa S. Mechanisms for asporin function and regulation in articular cartilage. J Biol Chem 2007; 282: 32185-32192 [PMID: 17827158 DOI: 10.1074/jbc.M700522200]
147. Krull NB, Gressner AM. Differential expression of keratan sulphate proteoglycans fibromodulin, lumican and aggrecan in normal and fibrotic rat liver. FEBS Lett 1992; 312: 47-52 [PMID: 1385211]
148. Mormone E, Lu Y, Ge X, Fiel MI, Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. Gastroenterology 2012; 142: 612-621.e5 [PMID: 22138190 DOI: 10.1053/j.gastro.2011.11.029]
149. Krishnan A, Li X, Kao WY, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest 2012; 92: 1712-1725 [PMID: 23007134 DOI: 10.1038/labinvest.2012.121]
150. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005; 15: 483-494 [PMID: 16045811 DOI: 10.1038/sj.cr.7290318]
151. Cross NA, Chandrasekharan S, Jokonya N, Fowles A, Hamdy FC, Buttle DJ, Eaton CL. The expression and regulation of ADAMTS-1,-4,-5,-9, and-15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 2005; 63: 269-275 [PMID: 15599946 DOI: 10.1002/pros.20182]
152. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96: 1560-1568 [PMID: 17453002 DOI: 10.1038/sj.bjc.6603766]
153. Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK, Tzanakakis GN. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 2006; 58: 47-53 [PMID: 16540432 DOI: 10.1080/15216540500531713]
154. Haase HR, Clarkson RW, Waters MJ, Bartold PM. Growth factor modulation of mitogenic responses and proteoglycan synthesis by human periodontal fibroblasts. J Cell Physiol 1998; 174: 353-361 [PMID: 9462697]
155. Tufvesson E, Westergren-Thorsson G. Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin-1beta and tumor necrosis factor-Alpha. J Cell Biochem 2000; 77: 298-309 [PMID: 10723095]
156. Aspberg A, Binkert C, Ruoslahti E. The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Proc Natl Acad Sci USA 1995; 92: 10590-10594 [PMID: 7479846]
157. Aspberg A, Adam S, Kostka G, Timpl R, Heinegård D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 1999; 274: 20444-20449 [PMID: 10400671]
158. Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, Sakai LY. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem 2002; 277: 4565-4572 [PMID: 11726670 DOI: 10.1074/jbc.M110583200]
159. Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem 1986; 261: 13526-13535 [PMID: 3759976]
160. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 2000; 275: 35448-35456 [PMID: 10950950 DOI: 10.1074/jbc.M003387200]
161. Zheng PS, Vais D, Lapierre D, Liang YY, Lee V, Yang BL, Yang BB. PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 2004; 117: 5887-5895 [PMID: 15522894 DOI: 10.1242/jcs.01516]
162. Wu Y, Chen L, Zheng PS, Yang BB. beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 2002; 277: 12294-12301 [PMID: 11805102 DOI: 10.1074/jbc.M110748200]
163. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-106 [PMID: 19122641 DOI: 10.1038/nature07623]
164. Zhang Y, Cao L, Kiani CG, Yang BL, Yang BB. The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 1998; 273: 33054-33063 [PMID: 9830060]
165. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, Yang BB. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 1999; 58: 597-605 [PMID: 10374750]
166. Xiang YY, Dong H, Wan Y, Li J, Yee A, Yang BB, Lu WY. Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J Biol Chem 2006; 281: 19358-19368 [PMID: 16648628 DOI: 10.1074/jbc.M512980200]
167. Sheng W, Dong H, Lee DY, Lu WY, Yang BB. Versican modulates gap junction intercellular communication. J Cell Physiol 2007; 211: 213-219 [PMID: 17219410 DOI: 10.1002/jcp.20921]
168. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002; 8: 1054-1060 [PMID: 11948113]
169. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ. Formation of hyaluronan-And versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007; 282: 10814-10825 [PMID: 17293599 DOI: 10.1074/jbc.M606991200]
170. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998; 4: 963-971 [PMID: 9563891]
171. Hanekamp EE, Gielen SC, Smid-Koopman E, Kühne LC, de Ruiter PE, Chadha-Ajwani S, Brinkmann AO, Grootegoed JA, Burger CW, Huikeshoven FJ, Blok LJ. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003; 9: 4190-4199 [PMID: 14519645]
172. Pukkila MJ, Kosunen AS, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Kellokoski JK, Nuutinen J, Kosma VM. Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J Clin Pathol 2004; 57: 735-739 [PMID: 15220367 DOI: 10.1136/jcp.2003.014589]
173. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, Kosma VM. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005; 36: 44-50 [PMID: 15712181 DOI: 10.1016/j.humpath.2004.10.010]
174. Kodama J, Hasengaowa T, Seki N, Matsuo T, Nakamura K, Hongo A, Hiramatsu Y. Versican expression in human cervical cancer. Eur J Cancer 2007; 43: 1460-1466 [PMID: 17446061 DOI: 10.1016/j.ejca.2007.02.007]
175. Morton SU, Scherz PJ, Cordes KR, Ivey KN, Stainier DY, Srivastava D. microRNA-138 modulates cardiac patterning during embryonic development. Proc Natl Acad Sci USA 2008; 105: 17830-17835 [PMID: 19004786 DOI: 10.1073/pnas.0804673105]
176. Wang X, Hu G, Zhou J. Repression of versican expression by microRNA-143. J Biol Chem 2010; 285: 23241-23250 [PMID: 20489207 DOI: 10.1074/jbc.M109.084673]
177. Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z, Yang BB. A 3'-untranslated region (3'UTR) induces organ adhesion by regulating miR-199a functions. PLoS One 2009; 4: e4527 [PMID: 19223980 DOI: 10.1371/journal.pone.0004527]
178. Fang L, Du WW, Yang X, Chen K, Ghanekar A, Levy G, Yang W, Yee AJ, Lu WY, Xuan JW, Gao Z, Xie F, He C, Deng Z, Yang BB. Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J 2013; 27: 907-919 [PMID: 23180826 DOI: 10.1096/fj.12-220905]
179. Xia L, Huang W, Tian D, Zhang L, Qi X, Chen Z, Shang X, Nie Y, Wu K. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology 2014; 59: 958-973 [PMID: 24005989 DOI: 10.1002/hep.26735]